{"entity":{"id":"ronan-kelly","kind":"person","name":"Ronan J. Kelly","aka":[],"tldr":"Led CheckMate 577, the first trial to show adjuvant immunotherapy helps oesophageal cancer patients with residual disease.","summary":"Ronan Kelly (Baylor Sammons Cancer Center) was principal investigator of CheckMate 577, which showed adjuvant nivolumab doubles disease-free survival in oesophageal and junctional cancer patients with residual disease after chemoradiotherapy and surgery, the first adjuvant immunotherapy approval in a GI cancer. He continues to lead perioperative immunotherapy trials in upper GI cancers.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kelly%20RJ%5BAuthor%5D%20esophageal%20nivolumab"}],"tags":["esophageal","immunotherapy","adjuvant"],"related":[],"cancers":["esophageal","gastric"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":["pd1"],"drugs":["nivolumab"],"companies":[],"institutions":["baylor-sammons-dallas"],"pathways":[],"terms":[],"trials":["checkmate-577"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["jnccn"],"dependsOn":[],"notes":[],"role":"Director, Charles A. Sammons Cancer Center, Baylor University Medical Center, Dallas","institutionId":"baylor-sammons-dallas","specialisms":["Oesophageal cancer","Gastric cancer","Adjuvant immunotherapy","Thoracic oncology"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kelly%20RJ%5BAuthor%5D%20esophageal%20nivolumab"}],"papers":[{"title":"Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (CheckMate 577)","journal":"NEJM","year":2021,"doi":"10.1056/NEJMoa2032125"},{"title":"Emerging multimodality approaches to treat localized esophageal cancer","journal":"Journal of the National Comprehensive Cancer Network","year":2019}],"orcid":"0000-0002-6446-2103"},"route":"/people/ronan-kelly/","neighbours":{"cancer":[{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"},{"id":"esophageal","kind":"cancer","name":"Oesophageal cancer","route":"/cancers/esophageal/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"target":[{"id":"pd1","kind":"target","name":"PD-1","route":"/targets/pd1/"}],"drug":[{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"}],"institution":[{"id":"baylor-sammons-dallas","kind":"institution","name":"Charles A. Sammons Cancer Center, Baylor University Medical Center","route":"/institutions/baylor-sammons-dallas/"}],"trial":[{"id":"checkmate-577","kind":"trial","name":"CheckMate 577","route":"/trials/checkmate-577/"}],"journal":[{"id":"jnccn","kind":"journal","name":"Journal of the National Comprehensive Cancer Network","route":"/journals/jnccn/"}]}}